Display options
Cite
Piao L, Mukherjee S, Chang Q, et al. TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget. 2016;8(36):60025-60035doi: 10.18632/oncotarget.10620.
Piao, L., Mukherjee, S., Chang, Q., Xie, X., Li, H., Castellanos, M. R., Banerjee, P., Iqbal, H., Ivancic, R., Wang, X., Teknos, T. N., & Pan, Q. (2017). TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget, 8(36), 60025-60035. https://doi.org/10.18632/oncotarget.10620
Piao, Longzhu, et al. "TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma." Oncotarget vol. 8,36 (2017): 60025-60035. doi: https://doi.org/10.18632/oncotarget.10620
Piao L, Mukherjee S, Chang Q, Xie X, Li H, Castellanos MR, Banerjee P, Iqbal H, Ivancic R, Wang X, Teknos TN, Pan Q. TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma. Oncotarget. 2016 Jul 16;8(36):60025-60035. doi: 10.18632/oncotarget.10620. eCollection 2017 Sep 01. PMID: 28947951; PMCID: PMC5601119.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2016 Jul 16;8(36):60025-60035. doi: 10.18632/oncotarget.10620. eCollection 2017 Sep 01.

TriCurin, a novel formulation of curcumin, epicatechin gallate, and resveratrol, inhibits the tumorigenicity of human papillomavirus-positive head and neck squamous cell carcinoma.

Oncotarget

Longzhu Piao, Sumit Mukherjee, Qing Chang, Xiujie Xie, Hong Li, Mario R Castellanos, Probal Banerjee, Hassan Iqbal, Ryan Ivancic, Xueqian Wang, Theodoros N Teknos, Quintin Pan

Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.
  2. Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  3. Ph.D. Program in Biochemistry at the Graduate Center of the City University of New York, New York, USA.
  4. Department of Chemistry and Center for Developmental Neuroscience, College of Staten Island, Staten Island, New York, USA.
  5. Department of Pathology and Laboratory Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA.
  6. Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  7. Division of Research, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA.

PMID: 28947951 PMCID: PMC5601119 DOI: 10.18632/oncotarget.10620

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600,000 new cases diagnosed in the last year. The incidence of human papillomavirus-positive head and neck squamous cell carcinoma (HPV-positive HNSCC) has rapidly increased over the past 30 years prompting the suggestion that an epidemic may be on the horizon. Therefore, there is a clinical need to develop alternate therapeutic strategies to manage the growing number of HPV-positive HNSCC patients. TriCurin is a composition of three food-derived polyphenols in unique stoichiometric proportions consisting of curcumin from the spice turmeric, resveratrol from red grapes, and epicatechin gallate from green tea. Cell viability, clonogenic survival, and tumorsphere formation were inhibited and significant apoptosis was induced by TriCurin in UMSCC47 and UPCI:SCC090 HPV-positive HNSCC cells. Moreover, TriCurin decreased HPV16E6 and HPV16E7 and increased p53 levels. In a pre-clinical animal model of HPV-positive HNSCC, intra-tumoral injection of TriCurin significantly inhibited tumor growth by 85.5% compared to vehicle group (

Keywords: catechin; curcumin; head and neck cancer; human papillomavirus; p53

Conflict of interest statement

CONFLICTS OF INTEREST No conflicts of interest to disclose.

References

  1. Mutat Res. 1999 Jul 16;428(1-2):305-27 - PubMed
  2. Front Biosci (Landmark Ed). 2012 Jun 01;17:2396-418 - PubMed
  3. Nutr Cancer. 2009;61(4):544-53 - PubMed
  4. Free Radic Biol Med. 2008 Nov 15;45(10):1403-12 - PubMed
  5. Front Biosci (Landmark Ed). 2013 Jun 01;18:1290-310 - PubMed
  6. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 - PubMed
  7. Int J Mol Sci. 2015 Feb 03;16(2):3350-76 - PubMed
  8. Int J Cancer. 2007 Feb 1;120(3):451-8 - PubMed
  9. Blood. 1998 Aug 1;92(3):996-1002 - PubMed
  10. Ann Surg Oncol. 2000 Sep;7(8):588-92 - PubMed
  11. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 - PubMed
  12. Cell Div. 2015 Oct 12;10:6 - PubMed
  13. Nat Rev Cancer. 2011 Jan;11(1):9-22 - PubMed
  14. Free Radic Biol Med. 1999 Jun;26(11-12):1531-7 - PubMed
  15. Eur J Cancer Prev. 2013 Nov;22(6):577-84 - PubMed
  16. Anticancer Res. 2015 Feb;35(2):645-51 - PubMed
  17. Radiat Oncol. 2011 Oct 26;6:144 - PubMed
  18. J Clin Oncol. 2006 Dec 20;24(36):5623-5 - PubMed
  19. J Clin Oncol. 2006 May 10;24(14):2137-50 - PubMed
  20. Gynecol Oncol. 2013 Apr;129(1):145-53 - PubMed
  21. Cancer Res Treat. 2014 Jan;46(1):2-18 - PubMed
  22. Drugs Exp Clin Res. 1999;25(2-3):115-20 - PubMed
  23. Head Neck. 2011 Jan;33(1):131-4 - PubMed
  24. Science. 1997 Jan 10;275(5297):218-20 - PubMed
  25. Antioxid Redox Signal. 2011 Nov 1;15(9):2605-41 - PubMed
  26. Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):200-20 - PubMed
  27. Biotechnol Adv. 2014 Nov 1;32(6):1053-64 - PubMed
  28. J Clin Oncol. 2013 Dec 20;31(36):4550-9 - PubMed
  29. Nutr Cancer. 2009;61(6):842-6 - PubMed
  30. Biochem Biophys Res Commun. 1999 Jan 27;254(3):739-43 - PubMed
  31. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50 - PubMed
  32. J Natl Cancer Inst. 2009 Mar 18;101(6):412-23 - PubMed
  33. Food Chem Toxicol. 2012 Dec;50(12):4421-7 - PubMed
  34. Invest New Drugs. 2010 Jun;28(3):216-24 - PubMed
  35. AAPS J. 2009 Sep;11(3):495-510 - PubMed
  36. Biochem Pharmacol. 2000 Apr 1;59(7):865-70 - PubMed
  37. Arch Pharm Res. 2009 Sep;32(9):1309-15 - PubMed
  38. Anticancer Agents Med Chem. 2014;14(10):1343-50 - PubMed
  39. Free Radic Biol Med. 1999 Jul;27(1-2):160-9 - PubMed
  40. Crit Rev Food Sci Nutr. 2005;45(4):287-306 - PubMed
  41. Oncogene. 2014 Feb 20;33(8):1037-46 - PubMed

Publication Types

Grant support